OverviewSuggest Edit

Fluidigm creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company's core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. Its products include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents.

TypePublic
Founded1999
HQSouth San Francisco, CA, US
Websitefluidigm.com
Employee Ratings3.6
Overall CultureB

Latest Updates

Employees (est.) (Dec 2019)566(+6%)
Revenue (FY, 2020)$138.1 M(+18%)
Share Price (Mar 2021)$4.8 (+4%)
Cybersecurity ratingBMore

Key People/Management at Fluidigm

Chris Linthwaite

Chris Linthwaite

President and CEO
Vikram Jog

Vikram Jog

Chief Financial Officer
Nick Khadder

Nick Khadder

Senior Vice President, General Counsel and Corporate Secretary
Colin McCracken

Colin McCracken

Chief Commercial Officer
Show more

Fluidigm Office Locations

Fluidigm has offices in South San Francisco, Sydney, Markham, Les Ulis and in 5 other locations
South San Francisco, CA, US (HQ)
7000 Shoreline Ct #100
South San Francisco, CA, US
2 Tower Pl Suite 2000
Sydney, AU
50 Bridge St
Markham, CA
1380 Rodick Rd #400
Les Ulis, FR
1 Avenue de l'Atlantique
München, DE
Landaubogen 10
Show all (12)

Fluidigm Financials and Metrics

Fluidigm Revenue

Fluidigm's revenue was reported to be $138.14 m in FY, 2020
USD

Revenue (FY, 2020)

138.1m

Net income (FY, 2020)

(53.0m)

EBIT (FY, 2020)

(51.0m)

Market capitalization (1-Mar-2021)

352.1m

Closing stock price (1-Mar-2021)

4.8

Cash (31-Dec-2020)

68.5m

EV

378.9m
Fluidigm's current market capitalization is $352.1 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

42.9m52.3m71.2m116.5m114.7m104.4m101.9m113.0m117.2m138.1m

Revenue growth, %

64%(1%)(9%)

Cost of goods sold

13.2m300.0k300.0k300.0k300.0k300.0k45.0m51.3m53.0m

Gross profit

29.7m52.0m70.9m116.2m114.4m104.1m56.9m61.6m64.3m
USDQ2, 2011

Financial Leverage

1.4 x
Show all financial metrics

Fluidigm Operating Metrics

FY, 2016

Patents Issued

600
Show all operating metrics

Fluidigm Revenue Breakdown

Embed Graph

Fluidigm revenue breakdown by geographic segment: 50.4% from United States, 28.5% from Europe, 17.7% from Asia-Pacific and 3.4% from Other

Fluidigm Cybersecurity Score

Cybersecurity ratingPremium dataset

B

85/100

SecurityScorecard logo

Fluidigm Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Fluidigm Online and Social Media Presence

Embed Graph

Fluidigm Company Culture

  • Overall Culture

    B

    80/100

  • CEO Rating

    A+

    85/100

  • Compensation

    A+

    100/100

Learn more on Comparably

Fluidigm News and Updates

Fluidigm Announces Collaboration with Zhejiang PuLuoTing Health Technology Co. Ltd to Market Fluidigm CyTOF Technology to Clinical Labs in China

PLT and Fluidigm Collaborate on Submission to the National Medical Products Administration for a CyTOF Device Approved for Diagnostic Use in China PLT and Fluidigm Collaborate on Submission to the National Medical Products Administration for a CyTOF Device Approved for Diagnostic Use in China

NASDAQ: FLDM Investor Notice: Lawsuit against Fluidigm Corporation announced by Shareholders Foundation

SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in NASDAQ: FLDM shares.

Key Regulatory Body in India Grants Commercial License for Fluidigm Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay

Fluidigm Assay is Among First Saliva-Based COVID-19 Tests Licensed for Use by Designated Labs in India Fluidigm Assay is Among First Saliva-Based COVID-19 Tests Licensed for Use by Designated Labs in India

Fluidigm to Participate at the Piper Sandler 32nd Annual Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that the company’s management will participate in the Piper Sandler 32nd…

FLDM FINAL DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Reminds Fluidigm Corporation Investors of Important November 20 Deadline in Securities Class Action – FLDM

NEW YORK, Nov. 20, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fluidigm Corporation (NASDAQ: FLDM) between February 7, 2019 and November 5, 2019, inclusive (the “Class Period”) of the important November 20, 2020 lead plaintiff…
Show more

Fluidigm Blogs

Fluidigm Announces Fourth Quarter and Full Year 2020 Financial Results

Fourth Quarter Total Revenue Increased 38 Percent to $44.6 million Fourth Quarter Product and Service Revenue Increased 26 Percent to $40.5 million Full Year Total Revenue Increased 18 Percent to $138.1 million Collaboration with PLT Tech to Market CyTOF Technology to Clinical Labs in China SOUTH

George Mason University Providing COVID-19 Testing with Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay on Biomark HD Platform

George Mason University Providing COVID-19 Testing with Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay on Biomark HD Platform Content Import Wed, 02/10/2021 - 16:03 George Mason University Providing COVID-19 Testing with Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay on Biomark HD Platfo…

Fluidigm to Participate in BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference

Fluidigm to Participate in BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference Content Import Thu, 02/04/2021 - 16:03 Fluidigm to Participate in BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference Feb 4, 2021 …

Fluidigm Receives CE-IVD Mark for Its Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay for COVID-19

SOUTH SAN FRANCISCO, Calif. , Jan. 21, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that the company has received the CE-IVD mark for its Advanta™ Dx

Fluidigm Announces Conference Call and Webcast of Fourth Quarter and Full Year 2020 Financial Results

SOUTH SAN FRANCISCO, Calif. , Jan. 07, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report fourth quarter and full year 2020 financial results

Dr. Ana K. Stankovic, MD, PhD, Appointed to Fluidigm Board of Directors

SOUTH SAN FRANCISCO, Calif. , Dec. 15, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the appointment of Dr. Ana K.
Show more

Fluidigm Frequently Asked Questions

  • When was Fluidigm founded?

    Fluidigm was founded in 1999.

  • Who are Fluidigm key executives?

    Fluidigm's key executives are Chris Linthwaite, Vikram Jog and Nick Khadder.

  • How many employees does Fluidigm have?

    Fluidigm has 566 employees.

  • What is Fluidigm revenue?

    Latest Fluidigm annual revenue is $138.1 m.

  • What is Fluidigm revenue per employee?

    Latest Fluidigm revenue per employee is $244.1 k.

  • Who are Fluidigm competitors?

    Competitors of Fluidigm include Aclara, Dren Bio and Accellta.

  • Where is Fluidigm headquarters?

    Fluidigm headquarters is located at 7000 Shoreline Ct #100, South San Francisco.

  • Where are Fluidigm offices?

    Fluidigm has offices in South San Francisco, Sydney, Markham, Les Ulis and in 5 other locations.

  • How many offices does Fluidigm have?

    Fluidigm has 12 offices.